List view / Grid view
17 April 2015 | By Victoria White
The primary endpoint has been met in the pivotal clinical trial MS-SPI of MD1003 in the treatment of progressive multiple sclerosis...
17 April 2015 | By Victoria White
CheckMate -057, a Phase III study evaluating Opdivo in patients with advanced non-squamous non-small cell lung cancer (NSCLC), has stopped early...
17 April 2015 | By Victoria White
MedImmune has entered into a collaboration with Immunocore to conduct immuno-oncology combination trials in metastic melanoma...
17 April 2015 | By Victoria White
Latest data from the ongoing AURA study of AZD9291 demonstrated a median progression free survival of 13.5 months in patients with advanced EGFRm NSCLC...
17 April 2015 | By Trelleborg Sealing Solutions
For the first time at INTERPHEX (International Pharmaceutical Expo), in Booth 3816, Trelleborg Sealing Solutions will showcase its engineered innovations for medical, biotech & pharmaceutical applications in silicone and other elastomers...
16 April 2015 | By Victoria White
Targacept has announced TC-6499 did not meet the primary endpoint of a Phase 1/2 exploratory study as a treatment for diabetic gastroparesis...
16 April 2015 | By Victoria White
Cardio3 BioSciences, a leader in engineered cell therapies, has announced its intention to change its corporate name to 'Celyad'...
16 April 2015 | By Victoria White
Isarna has initiated the Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-ß2 to treat advanced glaucoma...
16 April 2015 | By Victoria White
The FAMHP has given authorisation for the commencement of the Phase I clinical trial of FR104, a drug for controlling the regulation of the immune system...
16 April 2015 | By Victoria White
InVivo Therapeutics Holdings Corp. (NVIV) has announced that its common stock has been approved to begin trading on The Nasdaq Capital Market...
16 April 2015 | By Victoria White
Results from a multicentre, randomized, placebo-controlled phase II trial (BCT-001) of apremilast in patients with Behçet's disease have been published...
16 April 2015 | By Victoria White
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod and have released top line results for the 10TASQ10 study...
16 April 2015 | By Victoria White
Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis (MS)...
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
16 April 2015 | By Victoria White
Cellmid Limited has reported strong positive results in its independently conducted, blinded and placebo controlled human clinical study of évolis ONE...
